Biogen (NASDAQ:BIIB) had its Hold rating reiterated by JPMorgan Chase & Co.


Analyst Ratings For Biogen (NASDAQ:BIIB)

Today, JPMorgan Chase & Co. reiterated its Hold rating on Biogen (NASDAQ:BIIB).

There are 22 Hold Ratings, 7 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Biogen (NASDAQ:BIIB) is Hold with a consensus target price of $291.7750 per share, a potential 26.74% upside.

Some recent analyst ratings include

  • 4/24/2019-Biogen (NASDAQ:BIIB) had its Hold rating reiterated by JPMorgan Chase & Co.
  • 4/10/2019-Biogen (NASDAQ:BIIB) has coverage initiated with a Market Perform rating
  • 3/27/2019-Biogen (NASDAQ:BIIB) had its Hold rating reiterated by Cantor Fitzgerald with a $250.00 price target
  • 3/25/2019-Biogen (NASDAQ:BIIB) had its Buy ➝ Buy rating reiterated by HC Wainwright with a $300.00 price target

    About Biogen (NASDAQ:BIIB)
    Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

    Recent Trading Activity for Biogen (NASDAQ:BIIB)
    Shares of Biogen closed the previous trading session at 230,21 up +1,40 0,61 % with 228.27 shares trading hands.